GHRP-2

ASSUMED (based on receptor pharmacology confirmed in human cells and clinical GH secretion data, not direct mechanistic proof in vivo). GHRP-2 binds the ghrelin receptor (GHSR-1a) in pituitary somatotrophs, triggering calcium influx and protein kinase C activation, which stimulates GH exocytosis. Simultaneously activates hypothalamic GH-releasing pathways and suppresses somatostatin (the GH brake). Also activates ghrelin receptors in the hypothalamus to stimulate appetite via NPY/AgRP neurons. The cortisol/ACTH elevation reflects additional binding at corticotrophs.

• Reliably spikes GH in humans, confirmed in controlled studies and a Japanese diagnostic approval, but whether that pulse does anything useful for body composition in healthy adults is an open question.
• The cortisol and prolactin co-release are real and documented, not anecdote; that is the key reason ipamorelin exists as a cleaner alternative.
• Almost no one runs it alone. It is nearly always stacked with a GHRH analog, which makes it impossible to know what GHRP-2 is actually contributing to any outcome you see.

Adverse events

Consistently documented in human studies: cortisol and prolactin elevation (both transient, occur at standard doses), increased hunger/appetite, water retention, flushing, and transient drowsiness. The cortisol signal is notably stronger than ipamorelin. Cortisol and prolactin bumps are real signals from multiple controlled studies (Arvat 1997 PMID 9285939; Van den Berghe 2002 PMID 12030918), not anecdote.

Contraindications

Active cancer or family history of GH-responsive tumors. Diabetes or pre-diabetes (GH raises blood glucose acutely). Pregnancy or breastfeeding. History of pituitary adenoma.

Theoretical concerns

Chronic GH elevation carries theoretical risks including insulin resistance, fluid retention, and potential stimulation of latent neoplastic growth (GH is a growth factor). No long-term human safety data exists in healthy adults. Elevated prolactin with chronic use could cause gynecomastia or libido effects.

What nobody knows yet

Long-term effects of repeated pulsatile GH stimulation in healthy adults are completely unstudied. The primary human pharmacodynamic data is from IV bolus and continuous infusion protocols, not the subcutaneous bolus injection used by community protocols. Receptor desensitization kinetics with chronic dosing are not well characterized in humans. Interaction with TRT, GLP-1 agonists, and other peptide stacks has not been studied.

What else could explain the result

Almost universally stacked with GHRH analogs (CJC-1295 with or without DAC, modified GRF 1-29), which dramatically amplifies GH response and makes attribution impossible. Frequently co-administered with TRT, which independently improves body composition. Community users rarely run GHRP-2 alone. GLP-1 base effects (if on tirzepatide/semaglutide) suppress appetite, which directly opposes GHRP-2's orexigenic mechanism.

Is the vial what it says?

Compiled from the cited sources below. Where no completed human trial exists, the grade says so.

Half-life and storage

Half-life: Approximately 15-30 minutes plasma half-life (GH peak at 30-60 min post-subcutaneous injection). GH response returns to baseline within 90-120 minutes. Some sources report longer half-life (up to 2.5 hours in animal models). Short enough that timing relative to meals and training matters meaningfully.

Once mixed: Moderate. Reconstitute with bacteriostatic water. Keep refrigerated after reconstitution (stable approximately 30 days at 2-8C). Avoid repeated freeze-thaw. Exposure to elevated temperatures degrades the peptide.

What people report

Volume of reports: moderate. A real body of reports, fairly consistent.

High volume of community use and forum discussion, particularly in bodybuilding and anti-aging communities. One of the most discussed GH secretagogues alongside CJC-1295.

Reports are fairly consistent on the GH-pulse feel (flushing, hunger, heaviness post-injection) but body composition outcomes are inconsistent and heavily confounded by stacking.

Lower than volume suggests. Most reports are from stacked protocols. The GH pulse is real, but attributing specific body changes to GHRP-2 vs co-administered compounds is nearly impossible from community data.

• Anecdote: users consistently report a pronounced hunger spike 30-45 minutes after injection, sometimes described as uncomfortable. The one controlled human food-intake study we found tested the related peptide GHRP-2, not GHRP-6.
• Anecdote: post-injection flushing and a warm/heavy sensation are frequently described, particularly at higher doses. Attributed to the GH pulse and transient cortisol bump.
• Anecdote: some users report improved sleep depth, though this is not separated from the GH-during-sleep effect that occurs naturally or from co-administered CJC-1295.
• Anecdote: long-term users on community forums note plateau effects over weeks, consistent with GH secretagogue receptor desensitization.

Reports are anecdote, not proof.

Can you tell if it is working?

First documented human use: 1997. Arvat et al. published a controlled human comparison study (intravenous, dose-response) documenting GH, prolactin, ACTH, and cortisol elevation in 12 healthy men (6 young, 6 elderly). PMID 9285939.

1. 1980sGHRP-2 developed by Cyril Bowers and colleagues as part of a series of synthetic GH secretagogues based on enkephalin analogs.
2. 1997Arvat et al. publish a controlled human dose-response comparison of GHRP-2 and hexarelin vs GHRH in 12 men (6 young, 6 elderly), establishing that GHRPs elicit stronger GH responses than GHRH alone at equivalent IV doses (PMID 9285939).
3. 2002Van den Berghe et al. publish a 5-day randomized study of GHRP-2 alone vs GHRP-2 combined with TRH and GnRH in 33 critically ill men, documenting GH and cortisol elevation and metabolic effects (PMID 12030918).
4. 2004Pralmorelin (GHRP-2) approved in Japan by PMDA as a diagnostic agent for GH deficiency testing, marketed by Kaken Pharmaceutical. The pivotal Japanese trial data resides in the regulatory submission; a 2004 Drugs R&D review article (PMID 15230633) summarizes the development history, and described approval as pending at its December 2004 publication. Macimorelin, another GH secretagogue, was later approved by FDA (Dec 2017) as an oral diagnostic, and anamorelin is approved in Japan for cancer cachexia.
5. 2010s-presentGHRP-2 becomes popular in research and bodybuilding communities as an unscheduled peptide. No FDA approval for any indication. Sold as research chemical in the US.

• Arvat et al. 1997 - Effects of GHRP-2 and Hexarelin on GH, prolactin, ACTH and cortisol in man (PubMed 9285939). n=12 (6 young, 6 elderly). IV bolus only.(Core human comparative pharmacodynamic study. Single n=12 IV dose-response. Confirmed GH release plus cortisol/prolactin elevation. Route limitation: IV bolus, not subcutaneous.)
• Laferrere et al. 2005 - GHRP-2 increases food intake in healthy men (PMC2824650, PMID 15699539). n=7, continuous subcutaneous infusion.(Small but controlled crossover study in lean men. 36% caloric intake increase vs saline. Real human appetite signal. Used continuous infusion, not bolus injection.)
• Van den Berghe et al. 2002 - Combined GHRP-2, TRH and GnRH in critically ill men (PubMed 12030918). n=33 critically ill men.(5-day randomized study in critically ill patients, not healthy adults. Corroborates GH and cortisol elevation signal. Not a wellness or body composition study.)
• Drugs R&D 2004 review of pralmorelin development and Japanese approval (PubMed 15230633). Review article, not a primary trial.(Authoritative review summarizing pralmorelin clinical development history and PMDA approval. The underlying Japanese pivotal trial data is in the regulatory submission, not publicly available as a standalone English PubMed record.)
• Zhang et al. 2016 - GHRP-2 and cysteamine in yaks with growth retardation (PMC4760683). Animal model.(Animal model for muscle protein deposition claims. Often cited as if it proves human muscle benefit. It does not.)
• Ji et al. 2016 - GHRP-2 attenuation of inflammation in human ovarian granulosa cells (PMC5000754). In vitro cell study.(In vitro human cell study. Anti-inflammatory mechanism is plausible but this is not a clinical outcome study.)
• PMDA package insert for 注射用GHRP科研100 (pralmorelin hydrochloride), third edition revised July 2025; approval number 21600AMZ00573; dosage text matches the PMDA re-examination report of Feb 5, 2014(dose table)
• Arvat E et al. Peptides 1997;18(6):885-891. PMID 9285939. DOI 10.1016/s0196-9781(97)00016-8(dose table)
• Nijland EA et al. Eur J Endocrinol 1998;139(4):395-401. PMID 9820615. DOI 10.1530/eje.0.1390395(dose table)
• Mericq V et al. J Clin Endocrinol Metab 1998;83(7):2355-2360. PMID 9661608. DOI 10.1210/jc.83.7.2355(dose table)
• Laferrere B et al. J Clin Endocrinol Metab 2005;90(2):611-614. PMID 15699539. DOI 10.1210/jc.2004-1719(dose table)
• Bowers CY et al. J Clin Endocrinol Metab 2004;89(5):2290-2300. PMID 15126555. DOI 10.1210/jc.2003-031799(dose table)
• Van den Berghe G et al. Clin Endocrinol (Oxf) 2002;56(5):655-669. PMID 12030918. DOI 10.1046/j.1365-2265.2002.01255.x(dose table)
• Huberman Lab episode, Apr 1, 2024, transcript lines 'GHRP2, GHRP3, GHRP6' and 'GHRP2, 3, 6, and MK677, all of which can potently increase growth hormone'(dose table)